Summit's ivonescimab rejected by FDA, closing off near-term US launch in EGFR-mutant lung cancer
The regulator declined to approve the PD-1/VEGF bispecific after HARMONi showed a progression-free survival gain but no statistically significant overall survival benefit, Summit said.
Summit Therapeutics will not bring ivonescimab to the US market in previously treated EGFR-mutant lung cancer for now, after the Food and Drug Administration issued a complete response letter for its biologics licence application. The company disclosed the decision on 15 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Summit Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.